M. Neumaier, E. Schuck, T. Kaulisch, H. G. Niessen, D. Klatt, I. Sack, J. Braun, and D. Stiller In-Vivo Imaging Unit, Dept. of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, BW, Germany, Precision Mechanics, Dept. of Site Operations, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, BW, Germany, Dept. of Radiology, Charité University Medicine Berlin, Berlin, Ger...

Background: Caesarean section is one of the commonest operations performed all over the worlds and its incidence is increasing. As such, there are a number of immediate and delayed complications that may be encountered and the obstetrician must be familiar with and able to rectify these. Hence; we planned the present study to assess the maternal complications associated with cesarean sections. ...

The aim of our study was to improve the treatment of patients with stable Angina Pectoris functional class III with Hypertension and prevention of nitratoresistance development with usage of antioxidant (Mexicor) and NO-donor (L-arginine). The study involved 63 patients with stable angina pectoris FC III with concomitant Hypertension. All patients were divided into two groups. Patients of I gro...

Mitsubishi Pharma Corp and Novartis AG are developing fingolimod, an orally active immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis. Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts as a sphingosine-1-phosphate receptor agonist.

The technology is still in its early days, but will more pharmaceutical companies take the plunge? And will they fare better in the Twittersphere than they have in the blogosphere? To date, only a handful of pharmaceutical company blogs remain active. Among them are Johnson & Johnson’s site, JNJBTW (www.jnjbtw.com), up and running for more than two years, and GlaxoSmithKline’s (GSK’s) “ America...

There have been many resounding victories in the war against coronary artery disease. Among those are antiarrhythmic drugs, pacemakers, coronary bypass surgery, coronary angioplasty, reperfusion therapy, and statins. But the one goal that has continuously eluded us has been the clinical availability of an effective cardioprotective agent. Although reperfusion therapy has partially achieved the ...